Literature DB >> 24782427

4,6-Diaryl/heteroarylpyrimidin-2(1H)-ones as a new class of xanthine oxidase inhibitors.

Shiwani Shukla1, Dinesh Kumar, Ritu Ojha, Manish K Gupta, Kunal Nepali, Preet M S Bedi.   

Abstract

A series of 4,6-diaryl/heteroarylpyrimidones was synthesized employing silica-supported fluoroboric acid under solvent-free conditions in a microwave reactor. The catalytic influence of HBF4-SiO2 was investigated in detail to optimize the reaction conditions. The synthesized compounds were evaluated for in vitro xanthine oxidase (XO) inhibitory activity for the first time. Structure-activity relationship analyses are also presented. Among the synthesized compounds, VA-5, -9, -10, -12, -22, -23, and -25 were the active inhibitors with IC50 values ranging from 6.45 to 13.46 µM. Compound VA-25 with a pyridinyl ring as ring A and a thiophenyl ring as ring B emerged as the most potent XO inhibitor (IC50 = 6.45 µM) in comparison to allopurinol (IC50 = 12.24 µM). Some of the important interactions of VA-25 with the amino acid residues of the active site of XO were figured out by molecular modeling studies.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Catalyst; Fluoroboric acid; Inhibitors; Microwave radiation; Pyrimidones; Silica; Xanthine oxidase

Mesh:

Substances:

Year:  2014        PMID: 24782427     DOI: 10.1002/ardp.201400031

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  2 in total

1.  Identification of xanthine oxidase inhibitors through hierarchical virtual screening.

Authors:  Ying Yang; Lei Zhang; Jinying Tian; Fei Ye; Zhiyan Xiao
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

2.  Antitumour, acute toxicity and molecular modeling studies of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one against Ehrlich ascites carcinoma and sarcoma-180.

Authors:  Dinesh Kumar; Pooja Sharma; Kunal Nepali; Girish Mahajan; Mubashir J Mintoo; Amarinder Singh; Gurpreet Singh; Dilip M Mondhe; Gurdarshan Singh; Subheet K Jain; Girish K Gupta; Fidele Ntie-Kang
Journal:  Heliyon       Date:  2018-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.